• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Intelligent Bio Solutions Inc.

    4/29/25 8:21:58 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care
    Get the next $INBS alert in real time by email
    false 0001725430 DEFA14A 0001725430 2023-07-01 2024-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934 (Amendment No. )

     

    Filed by the Registrant ☒

     

    Filed by a party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐ Definitive Proxy Statement
    ☒ Definitive Additional Materials
    ☐ Soliciting Material Pursuant to §240.14a-12

     

    Intelligent Bio Solutions Inc.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):
       
    ☒ No fee required.
       
    ☐ Fee paid previously with preliminary materials.
       
    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

     

     

    Intelligent Bio Solutions Inc.

    135 West, 41st Street, 5th Floor

    New York, NY 10036

    SUPPLEMENT TO PROXY STATEMENT

    FOR THE ANNUAL MEETING OF STOCKHOLDERS

    TO BE HELD ON MAY 8, 2025

     

    Explanatory Note

     

    On April 1, 2025, Intelligent Bio Solutions Inc. (the “Company”) filed its definitive proxy statement (as updated by the supplement to the proxy statement filed by the Company on April 28, 2025, the “Proxy Statement”) in connection with the solicitation of proxies by the Board of Directors of the Company for use at the Annual Meeting of Stockholders to be held on May 8, 2025, at 3:30 p.m. Eastern Time (the “Annual Meeting”).

     

    The Company is filing this supplement to the Proxy Statement (this “Supplement”) solely for the purpose of including the required Inline XBRL tagging of certain disclosures in the Proxy Statement found under the heading “Policy with Respect to Insider Trading and Hedging Transactions” (on page 12 of the Proxy Statement) and “Granting of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information” (on page 18 of the Proxy Statement), which Inline XBRL tagging was inadvertently omitted. Other than the inclusion of Inline XBRL tagging, which revisions are set forth below, no other information in the Proxy Statement has been revised, supplemented, updated or amended by this Supplement.

     

    This Supplement should be read in conjunction with the Proxy Statement. The information contained in this Supplement modifies or supersedes any inconsistent information contained in the Proxy Statement. Capitalized terms used herein and not otherwise defined have the meaning given to such terms in the Proxy Statement.

     

    Supplement

     

    Policy with Respect to Insider Trading and Hedging Transactions

     

    We have adopted an Insider Trading Policy that provides guidance to employees (including officers) and directors with respect to transactions in the Company’s securities. The Insider Trading Policy is designed to promote compliance with insider trading laws, rules and regulations and any listing standards applicable to the Company. The policy also prohibits directors, officers and other employees from purchasing financial instruments (including prepaid variable forward contracts, equity swaps, collars, and exchange funds), or otherwise engaging in transactions, that hedge or offset, or are designed to hedge or offset, any decrease in the market value of our equity securities without our prior approval. It is also the Company’s policy to comply with all applicable securities laws when transacting in its own securities.

     

    Granting of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information

     

    We do not grant stock options, stock appreciation rights, or option-like instruments (collectively, “Option-Like Awards”) in anticipation of the release of material nonpublic information and we do not time the public release of such information based on the grant dates of Option-Like Awards. During the last completed fiscal year, we have not awarded Option-Like Awards to any named executive officer during the period beginning four business days before and ending one business day after the filing of a period report on Form 10-Q or Form 10-K or the filing or furnishing of a current report on Form 8-K, and we have not timed the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.

     

     

     

     

     

    Get the next $INBS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INBS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $INBS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026 Revenue Growth of Approximately 48% Year-Over-Year, Surpassing $2 Million in Total Revenue for First Half of Fiscal Year

    Expected record fiscal second quarter revenue increase driven by expanding customer base and strong growth across all product categories Reader sales expected to post year-over-year growth of more than 100% in fiscal Q2, expanding installed base to drive sustained recurring cartridge revenue NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary, unaudited revenue results for the fiscal second quarter and first half 2026 ended December 31, 2025. The Company expects to report strong revenue growth across all pr

    2/5/26 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Initiates Additional Clinical Studies for FDA 510(k) Submission Supporting Planned Entry into Multi-Billion Dollar U.S. Market

    Clinical studies designed to support FDA clearance and planned commercial launch into the world's largest drug screening market  Company anticipates full data analysis by the end of March 2026; data to be incorporated into FDA 510(k) submission package NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the commencement of its clinical study program to support its new FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine. As part of

    1/28/26 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Announces Closing of $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

    NEW YORK, Jan. 02, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (NASDAQ:INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the closing of its previously announced private placement with two healthcare focused institutional investors priced at-the-market under Nasdaq rules of 2,298,850 shares of common stock (or pre-funded warrants in lieu thereof), Series K-1 warrants to purchase up to an aggregate of 2,298,850 shares of common stock and Series K-2 warrants to purchase up to an aggregate of 2,298,850 shares of common stock, at a combined purchase price of $4.35 per share of common stock (or

    1/2/26 5:00:00 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $INBS
    SEC Filings

    View All

    Intelligent Bio Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

    2/5/26 8:53:26 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

    1/28/26 5:15:25 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Intelligent Bio Solutions Inc.

    EFFECT - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

    1/22/26 12:15:16 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $INBS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Sakiris Spiro Kevin was granted 34,500 shares, increasing direct ownership by 10,952% to 34,815 units (SEC Form 4)

    4/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

    3/31/25 4:15:27 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Simeonidis Harry was granted 40,000 shares, increasing direct ownership by 9,804% to 40,408 units (SEC Form 4)

    4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

    9/27/24 5:00:16 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Sakiris Spiro Kevin was granted 34,500 shares, increasing direct ownership by 10,952% to 34,815 units (SEC Form 4)

    4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

    9/27/24 5:00:15 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $INBS
    Financials

    Live finance-specific insights

    View All

    Intelligent Bio Solutions Reports Fiscal 2026 First Quarter Financial Results and Operational Highlights, Delivering Record Revenue Growth

    Record quarterly revenue of $1.11 million, an increase of 32% sequentially and 28% year-over-year, driven by consumable cartridge sales and customer base expansion Gross profit margins increased 690 basis points year-over-year to 46.6%, reflecting improved operational efficiency and greater revenue percentage from higher margin cartridge sales NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal first quarter ended September 30, 2025. The fiscal 2026 first

    11/12/25 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Reports Fiscal 2025 Fourth Quarter and Full Year Results, Highlighting Progress on Planned U.S. Market Expansion, Revenue Growth and Increased Operational Efficiencies

    Company advanced efforts to secure U.S. FDA 510(k) clearance to advance on path towards planned U.S. market expansion beyond Forensic Use Only settings Fourth quarter sequential and year-on-year revenue growth of 16%, supported by increased demand for drug testing cartridges NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal fourth quarter and full-year ended June 30, 2025. Fiscal 2025 marked a year of growth for the Company, driven by higher-margin cart

    8/15/25 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements

    20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended March 31, 2025  35 new accounts and international growth during Q3 bring total active accounts to over 450 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal third quarter and nine months ended March 31, 2025, and provided a business update.   The Company delivered a st

    5/13/25 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $INBS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

    SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 7:16:17 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Intelligent Bio Solutions Inc.

    SC 13G - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 4:31:30 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care